Novartis To Close R&D Facility In Japan By Year’s End
This article was originally published in PharmAsia News
Executive Summary
The Swiss company Novartis says it will close its research-and-development facility in Japan by the end of 2008. In doing so, Novartis would be joining several other major multinational pharmaceutical manufacturers in closing R&D facilities in the country. The Novartis Tsukuba Research Institute, was established in 1993 to develop new drugs for the company's Japanese subsidiary, Novartis Pharma KK. The Japan R&D work is to be merged with Novartis operations in the United States as part of a cost-cutting move. (Click here for more - may require a subscription
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.